Several biomarkers potentially involved in the development of sarcopenia such as tissue growth factor (TGF)-β and interleukin (IL)-6 are considered as factors that might impair tumour response to immune checkpoint inhibitors. The gene discussed is IL6; the disease is neoplasm.